2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2181

Development and Feasibility of a Web-Based Data Capture System to Collect Uniform Comprehensive Post-Total Knee Replacement Physical Therapy Intervention Data for Both Clinical and Research Purposes
Abstract Number: 2671

Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
Abstract Number: 331

Development and Implementation of a Patient-Reported Outcomes Measurement Information System (MyRheum)
Abstract Number: 1394

Development and Pilot of a Patient Satisfaction Scale in Rheumatology
Abstract Number: 314

Development and Preliminary Validation of an Omeract Magnetic Resonance Imaging (MRI) Scoring System for Ankle Enthesitis in Spondyloarthritis
Abstract Number: 1860

Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects
Abstract Number: 2474

Development of a Crosswalk for FACIT-10 (Psychometric Work)
Abstract Number: 320

Development of a Magnetic Resonance Imaging Atlas for the Classification of Osteoarthritis of the First Metatarsophalangeal Joint
Abstract Number: 2816

Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 1042

Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis
Abstract Number: 2141

Development of a Pediatric Glucocorticoid Toxicity Index
Abstract Number: 1455

Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence
Abstract Number: 2910

Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials
Abstract Number: 2959

Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Abstract Number: 2514

Development of a Subcutaneous Formulation of CT-P13 (Infliximab): Maintenance Subcutaneous Administration May Elicit Lower Immunogenicity Compared to Intravenous Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].